Comparison of copper-67- and iodine-125-labeled anti-CEA monoclonal antibody biodistribution in patients with colorectal tumors.

Détails

ID Serval
serval:BIB_2F737E5BD70C
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Institution
Titre
Comparison of copper-67- and iodine-125-labeled anti-CEA monoclonal antibody biodistribution in patients with colorectal tumors.
Périodique
Journal of Nuclear Medicine
Auteur(s)
Delaloye A.B., Delaloye B., Buchegger F., Vogel C.A., Gillet M., Mach J.P., Smith A., Schubiger P.A.
ISSN
0161-5505 (Print)
ISSN-L
0161-5505
Statut éditorial
Publié
Date de publication
1997
Peer-reviewed
Oui
Volume
38
Numéro
6
Pages
847-853
Langue
anglais
Résumé
Copper-67 has comparable beta-particle emissions to that of 131I, but it displays more favorable gamma emission characteristics for application in radioimmunotherapy (RIT). This study investigates the potential of 67Cu-labeled monoclonal antibody (MAb) 35 for RIT of colorectal carcinoma.
METHODS: Biokinetics of simultaneously injected 67Cu- and 125I-labeled MAb35 were studied in six patients scheduled for surgery of primary colorectal cancer.
RESULTS: Whole-body clearance (T 1/2) of 67Cu, estimated from sequential anterior and posterior whole-body scans and corrected for decay of 67Cu, was 41 hr. Serum clearance of 67Cu was faster (27.41 hr) than that of 125I (38.33 hr). Mean tumor uptake of the 67Cu-labeled compound (0.0133% ID/g) exceeded that of 125I (0.0095% ID/g), and tumor-to-blood ratios were higher for 67Cu than for 125I, with averages of 6.07 and 2.41, respectively. The average 67Cu/125I ratio was 1.9 for tumor uptake, 0.7 for blood and 2.6 for tumor-to-blood ratios. Nonspecific liver uptake of 67Cu as calculated from whole-body scans was high in four patients, up to 25% of residual whole-body activity at 48 hr, but did not increase with time. We also observed some nonspecific bowel activity, as well as moderate to high uptake in benign polyps.
CONCLUSION: Copper-67-labeled MAb35 is more favorable than its radioiodine-labeled counterpart for RIT of colorectal carcinoma due to higher tumor-to-blood ratios, but the problem of nonspecific liver and bowel uptake must first be overcome. The absolute accumulation of activity in tumor remains low, however, so the probability of cure with this compound alone is questionable. The use of 67Cu as one component of a multimodality adjuvant treatment seems to remain the most appropriate application for RIT.
Mots-clé
Aged, Antibodies, Monoclonal/pharmacokinetics, Antibodies, Monoclonal/therapeutic use, Carcinoembryonic Antigen/immunology, Colorectal Neoplasms/metabolism, Colorectal Neoplasms/radiotherapy, Copper Radioisotopes/pharmacokinetics, Copper Radioisotopes/therapeutic use, Female, Humans, Iodine Radioisotopes/pharmacokinetics, Iodine Radioisotopes/therapeutic use, Male, Radioimmunotherapy, Tissue Distribution
Pubmed
Web of science
Création de la notice
25/01/2008 11:27
Dernière modification de la notice
20/08/2019 13:13
Données d'usage